Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.39 |
| ▸ | CDC25B | P30305 | 9/20 | 0.39 |
| ▸ | SELP | P16109 | 3/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314141 | 0.90 | SELP (0.41) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL10314139 | 0.89 | SELP (0.39) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL10314137 | 0.89 | SELP (0.47) | PTPN1CDC25BSELPNT5E | |
| SCHEMBL10314133 | 0.88 | SELP (0.50) | PTPN1CDC25BSELP | |
| SCHEMBL10314148 | 0.83 | PTPN1 (0.48) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL12202034 | 0.80 | PTPN1 (0.46) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL12202038 | 0.80 | PTPN1 (0.46) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL12202025 | 0.78 | PTPN1 (0.45) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL12202042 | 0.78 | PTPN1 (0.45) | PTPN1CDC25BSELPNT5EPTPN2 | |
| SCHEMBL12202028 | 0.78 | PTPN1 (0.45) | PTPN1CDC25BSELPNT5EPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211859-B2 | α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GALE, GALNT14, GALC | PTPN1 4777/4885CDC25B 2094/4885SELP 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.